Aurora Cannabis Files Q3 2024 Interim Financials for Dec 31, 2023

TL;DR

**Aurora Cannabis just dropped its Q3 2024 financials, time to see how they're doing!**

AI Summary

Aurora Cannabis Inc. filed a 6-K on February 8, 2024, for the period ending December 31, 2023, which includes their unaudited Condensed Consolidated Interim Financial Statements and Interim Management's Discussion and Analysis. This filing, signed by CFO Glen Ibbott, indicates the company is providing its Q3 2024 financial results (for the three and nine months ended December 31, 2023 and 2022) to investors. This matters to shareholders because it provides crucial insight into the company's recent financial performance, including revenue, expenses, and profitability, which can influence stock valuation and future investment decisions.

Why It Matters

This filing provides investors with Aurora Cannabis's latest financial health report, allowing them to assess performance and make informed decisions about holding or buying the stock.

Risk Assessment

Risk Level: medium — The filing itself is routine, but the financial results contained within (Exhibits 99.1 and 99.2) could reveal positive or negative performance, impacting stock price.

Analyst Insight

Investors should review the attached Exhibits 99.1 (financial statements) and 99.2 (MD&A) to understand Aurora Cannabis's financial performance for Q3 2024 and assess its implications for future growth and profitability.

Key Numbers

• December 31, 2023 — Reporting Period End Date (The date for which the Condensed Consolidated Interim Financial Statements and Interim Management's Discussion and Analysis are provided.)
• February 08, 2024 — Filing Date (The date Aurora Cannabis Inc. officially filed this 6-K report with the SEC.)

Key Players & Entities

• Aurora Cannabis Inc. (company) — registrant filing the 6-K
• Glen Ibbott (person) — Chief Financial Officer who signed the 6-K
• 001-38691 (other) — Commission File No. for Aurora Cannabis Inc.
• February 8, 2024 (date) — date the 6-K was filed
• December 31, 2023 (date) — end of the reporting period for the interim financial statements

FAQ

From the Filing

0001683541-24-000005.txt : 20240208 0001683541-24-000005.hdr.sgml : 20240208 20240208071027 ACCESSION NUMBER: 0001683541-24-000005 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240208 DATE AS OF CHANGE: 20240208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AURORA CANNABIS INC CENTRAL INDEX KEY: 0001683541 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38691 FILM NUMBER: 24606844 BUSINESS ADDRESS: STREET 1: 2207 90B STREET SW CITY: EDMONTON STATE: A0 ZIP: T6X 1V8 BUSINESS PHONE: 604-362-5207 MAIL ADDRESS: STREET 1: 409 GRANVILLE STREET STREET 2: SUITE 1700 CITY: VANCOUVER STATE: A1 ZIP: V6C 1T2 6-K 1 form6-k20231231q32024.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File No. 001-38691 AURORA CANNABIS INC. (Translation of registrant's name into English) 2207 90B St. SW Edmonton, Alberta T6X 1V8 Canada (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F   [ ] Form 40-F  [X] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)  [ ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)  [ ] This Form 6-K is hereby filed and incorporated by reference in the registrant’s Registration Statement on Form F-10 (File No. 333-271479). SUBMITTED HEREWITH Exhibits Description 99.1 Condensed Consolidated Interim Financial Statements for the three and nine months ended December 31, 2023 and 2022 99.2 Interim Management’s Discussion and Analysis for the three and nine months ended December 31, 2023 and 2022 99.3 Certification of Chief Executive Officer 99.4 Certification of Chief Financial Officer      SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AURORA CANNABIS INC. /s/ Glen Ibbott              Glen Ibbott Chief Financial Officer Date: February 08, 2024      EX-99.1 2 fs20231231q32024.htm EX-99.1 Document AURORA CANNABIS INC. Condensed Consolidated Interim Financial Statements (Unaudited) For the three and nine months ended December 31, 2023 and 2022 (in Canadian Dollars) Table of Contents Condensed Consolidated Interim Statements of Financial Position 3 Condensed Consolidated Interim Statements of Loss and Comprehensive Loss 4 Condensed Consolidated Interim Statements of Changes in Equity 6 Condensed Consolidated Interim Statements of Cash Flows 8 Notes to the Condensed Consolidated Interim Financial Statements Note 1 Nature of Operations 9 Note 11 Loss per share 19 Note 2 Significant Accounting Policies and Judgments 9 Note 12 Other Gains (Losses) 19 Note 3 Marketable Securities 10 Note 13 Supplemental Cash Flow Information 20 Note 4 Biological Assets 11 Note 14 Commitments and Contingencies 20 Note 5 Inventory 12 Note 15 Revenue 22 Note 6 Property, Plant and Equipment 13 Note 16 Segmented Information 23 Note 7 Assets Held for Sale and Discontinued Operations 14 Note 17 Fair Value of Financial Instruments 24 Note 8 Convertible Debentures 16 Note 18 Financial Instruments Risk 25 Note 9 Loans and Borrowings 16 Note 19 Subsequent Events 27 Note 10 Share Capital 18 AURORA CANNABIS INC. Con